S762
Clinical - Lung
ESTRO 2026
Biomarkers
(P=0.01), reflecting progressive concentric hypertrophy. At baseline, older patients (P=0.03) and females (P<0.001) had more concentric hypertrophy. During follow-up, females (P=0.02), patients without cardiac disease (P=0.03), and those with lung cancer (P=0.03) showed this pattern. Response was blunted in patients with pre-existing cardiac comorbidities (P=0.02), indicating limited hypertrophic adaptation (Figure 2).PC3 increased in the second half of follow- up (P<0.01), reflecting hypertrophy and outflow obstruction. At baseline, this was strongest in male patients (P<0.01). During follow-up, males (P=0.02) and patients with pre-existing cardiac disease (P=0.03) showed more hypertrophy and outflow obstruction.Higher PC4 scores represent greater cardiac output. PC4 remained largely stable throughout follow-up (lowest P=0.10). At baseline, cardiac output was lowest in oesophageal cancer patients (P<0.01) and those with pre-existing cardiac comorbidities (P<0.001). Post-treatment increase was strongest in hypertensive patients (P=0.02) (Figure 2).Figure 2 Less concentric hypertrophy (PC2) with cardiac comorbidity (P=0.02), and more increase of cardiac output (PC4) with baseline hypertension (P=0.02)
Digital Poster Highlight 699 Durvalumab improves progression-free survival and sequential radiotherapy improves locoregional and local control in elderly NSCLC Stage III patients Brane Grambozov 1 , Josef Karner 1 , Markus Stana 1 , Elvis Ruznic 1 , Barbara Zellinger 2 , Marisa Klebermass 3 , Ayurzana Purevdorj 4 , Georg Gruber 5 , Danijela Minasch 6 , Martin Heilmann 7 , Raphaela Moosbrugger 8 , Falk Roeder 1,9 , Franz Zehentmayr 1 1 Radiation Oncology, Paracelsus Medical University, SALK, Salzburg, Austria. 2 Institute of Pathology, Paracelsus Medical University, SALK, Salzburg, Austria. 3 Radiation Oncology, Klinikum Ottakring, Vienna, Austria. 4 Radiation Oncology, Klinikum Hietzing- Rosenhügel, Vienna, Austria. 5 Radiation Oncology, Ordensklinikum Linz, Linz, Austria. 6 Radiation Oncology, Comprehensive Cancer Centre, Medical University Innsbruck, Innsbruck, Austria. 7 Radiation Oncology, Comprehensive Cancer Centre, Medical University Vienna, Vienna, Austria. 8 Pneumology, Paracelsus Medical University, SALK, Salzburg, Austria. 9 Institute for Research and Development on Advanced Radiation Technologies, Paracelsus Medical University, Salzburg, Salzburg, Austria Purpose/Objective: The incidence of NSCLC increases with age, with a median of approximately 70 years at diagnosis. Historically, treatment strategies for locally advanced cancers have been developed predominantly in younger populations, often excluding elderly patients who may present with multiple comorbidities, severely impaired lung function, or decreased performance status, leading to a lack of age-relevant clinical data. Therefore we performed a subanalysis of real-world data from the ALLSTAR study to investigate the impact of durvalumab and the radiation regimen (sequential versus concurrent) on clinical outcome in elderly patients with unresectable stage III NSCLC. Material/Methods: We included a total of 171 patients in this subanalysis. All patients were diagnosed with unresectable stage III NSCLC. Patients were divided into two age groups, ≥ 70 (41%) and <70 years (59%). All of them received curative chemo-radiotherapy with (66%) or without (34%) durvalumab. Results: Patients were followed up for a median time of 25.1 months (range:3.3-52.1). The mean (median not reached) overall survival (OS) in the whole cohort was 36.0 months (95% CI: 33.0–38.9), compared to 36.6 months (95% CI: 31.8–39.4) in the <70s age group and
Conclusion: Chemoradiotherapy causes time-dependent cardiac changes in right atrial pressure, ventricular hypertrophy, and cardiac output. Changes vary by age, sex, tumour type, and comorbidity, underscoring the
need for personalized monitoring and care. Keywords: Cardiotoxicity, Echocardiography,
Made with FlippingBook - Share PDF online